Leukemia stem cells (LSCs) initiate and sustain the acute myeloid leukemia (AML) clonal hierarchy and possess biological properties rendering them resistant to conventional chemotherapy. The poor survival of AML patients raises expectations that LSC-targeted therapies might achieve durable remissions. We report that an anti-interleukin-3 (IL-3) receptor alpha chain (CD123)-neutralizing antibody (7G3) targeted AML-LSCs, impairing homing to bone marrow (BM) and activating innate immunity of nonobese diabetic/severe-combined immunodeficient (NOD/SCID) mice. 7G3 treatment profoundly reduced AML-LSC engraftment and improved mouse survival. Mice with pre-established disease showed reduced AML burden in the BM and periphery and impaired secondary transplantation upon treatment, establishing that AML-LSCs were directly targeted. 7G3 inhibited IL-3-mediated intracellular signaling of isolated AML CD34(+)CD38(-) cells in vitro and reduced their survival. These results provide clear validation for therapeutic monoclonal antibody (mAb) targeting of AML-LSCs and for translation of in vivo preclinical research findings toward a clinical application.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.stem.2009.04.018 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The β Common Cytokine Receptor Family Reveals New Functional Paradigms From Structural Complexities.
Immunol Rev
January 2025
Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Parkville, Victoria, Australia.
Cytokines are small proteins that are critical for controlling the growth and activity of hematopoietic cells by binding to cell surface receptors and transmitting signals across membranes. The β common (βc) cytokine receptor family, consisting of the granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin (IL)-3, and IL-5 cytokine receptors, is an architype of the heterodimeric cytokine receptor systems. We now know that signaling by cytokine receptors is not always an "all or none" phenomenon.
View Article and Find Full Text PDFLoop33 × 123 CAR-T targeting CD33 and CD123 against immune escape in acute myeloid leukemia.
Cancer Immunol Immunother
November 2024
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 288 Nanjing Road, Tianjin, 300020, China.
Background: Immunotherapy, such as chimeric antigen receptor T (CAR-T) cells targeting CD33 or CD123, has been well developed over the past decade for the treatment of acute myeloid leukemia (AML). However, the inability to sustain tumor-free survival and the possibility of relapse due to antigen loss have raised concerns. A dual targeting of CD33 and CD123 is needed for better outcomes.
View Article and Find Full Text PDFEpitope prime editing shields hematopoietic cells from CD123 immunotherapy for acute myeloid leukemia.
Cell Stem Cell
November 2024
Department of Rheumatology and Immunology, Medical Research Institute, Frontier Science Center for Immunology and Metabolism, Zhongnan Hospital of Wuhan University, Wuhan University, Wuhan 430071, China; TaiKang Centre for Life and Medical Sciences, TaiKang Medical School, Wuhan University, Wuhan 430071, China; State Key Laboratory of Virology, Wuhan University, Wuhan 430071, China. Electronic address:
Article Synopsis
- Acute myeloid leukemia (AML) causes abnormal growth of blood stem cells, making it challenging to treat with CAR-T cell therapies due to harmful effects on normal cells.
- Researchers modified the CD123 antigen on healthy stem cells using advanced gene-editing techniques (base and prime editing) to protect them from CAR-T attacks while preserving their function.
- The modified stem cells showed resistance to CAR-T cell lysis in humanized mice, providing an innovative approach for effectively treating relapsed AML.
A γδ T cell-IL-3 axis controls allergic responses through sensory neurons.
Nature
October 2024
Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
In naive individuals, sensory neurons directly detect and respond to allergens, leading to both the sensation of itch and the activation of local innate immune cells, which initiate the allergic immune response. In the setting of chronic allergic inflammation, immune factors prime sensory neurons, causing pathologic itch. Although these bidirectional neuroimmune circuits drive responses to allergens, whether immune cells regulate the set-point for neuronal activation by allergens in the naive state is unknown.
View Article and Find Full Text PDF[Clinical characteristics and prognosis of childhood acute lymphoblastic leukemia with CD123 expression].
Zhongguo Dang Dai Er Ke Za Zhi
July 2024
Department of Hematology and Oncology, Kunming Children's Hospital/Children's Hospital Affiliated to Kunming Medical University, Kunming 650228, China.
Objectives: To investigate the expression of CD123 in children with acute lymphoblastic leukemia (ALL) and its effect on the clinical characteristics and prognosis of children with B-lineage acute lymphoblastic leukemia (B-ALL).
Methods: A retrospective analysis was conducted on the clinical data of 251 children with ALL who were admitted to the Department of Hematology and Oncology, Children's Hospital of Kunming Medical University, from December 2019 to June 2022. According to the expression of CD123 at initial diagnosis, the children were divided into CD123 group and CD123 group, and the two groups were compared in terms of clinical characteristics and treatment outcome.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!